Conditions: Multiple Myeloma
Keywords: IGF-1R inhibitor CP-751871 multiple myeloma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 47
Healthy volunteers: no

Brief summary:
This study represents the first-in-human study for CP-751,871. The study aimed to define the safety, tolerability, and maximum tolerated dose of CP-751,871 in patients with multiple myeloma through a dose escalation design.

Detailed description:

Arms:
arm 1: dose escalation design

Interventions: intervention 1: CP-751,871
Intervention descriptions: intervention 1: CP-751,871 was given at doses ranging from 0.025 mg/kg up to 20 mg/kg IV every 4 weeks until disease progression or lack of tolerability

Protocol document: